Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a 'chemosensitive' relapse: A single-arm phase II study (EORTC-08061)

Fatma Abdelraouf, Egbert Smit, Baktiar Hasan, Jessica Menis, Sanjay Popat, Jan P. van Meerbeeck, Veerle F. Surmont, Paul Baas, Mary O'Brien

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)35-39
JournalEuropean Journal of Cancer
Volume54
DOIs
Publication statusPublished - Feb 2016

Keywords

  • Phase II study
  • SCLC
  • Second-line treatment
  • Sunitinib
  • Targeted therapy
  • Tyrosine kinase inhibitor

Cite this